^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AL2846

    i
    Other names: AL2846, AL-2846, AL 2846
    Associations

    News

    Trials
    Company:
    Advenchen, Sino Biopharm
    Drug class:
    c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. (PubMed, Cancer)
    Combined TQB2450 and AL2846 therapy exhibited a favorable safety profile in immunotherapy-refractory patients with advanced ESCC and HCC.
    P1 data • Journal • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4)
    |
    benmelstobart (APL-502) • AL2846
    8ms
    A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov)
    P1/2, N=22, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=192 --> 22 | Trial completion date: Dec 2024 --> Feb 2024 | Recruiting --> Terminated; sponsor adjusts its research and development strategy
    Enrollment change • Trial completion date • Trial termination
    |
    NF1 (Neurofibromin 1)
    |
    NF1 mutation
    |
    AL2846
    9ms
    A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=34, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial • Metastases
    |
    gemcitabine • AL2846
    1year
    A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=135, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • pemetrexed • benmelstobart (APL-502) • AL2846
    over1year
    Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. (clinicaltrials.gov)
    P3, N=518, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial • Metastases
    |
    docetaxel • benmelstobart (APL-502) • AL2846
    3years
    A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov)
    P1/2, N=192, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    NF1 (Neurofibromin 1)
    |
    NF1 mutation
    |
    AL2846
    3years
    A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (clinicaltrials.gov)
    P1/2, N=192, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P1/2 trial
    |
    NF1 (Neurofibromin 1)
    |
    NF1 mutation
    |
    AL2846
    4years
    A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (clinicaltrials.gov)
    P2, N=60, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Sep 2020
    Clinical • Enrollment open • Trial initiation date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor)
    |
    zoledronic acid • AL2846
    over4years
    A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor)
    |
    zoledronic acid • AL2846